ENHANCED IN VITRO HEMOSTASIS AND REDUCED THROMBOLYSIS IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS
- 1 May 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 49 (5) , 905-909
- https://doi.org/10.1097/00007890-199005000-00014
Abstract
In vitro hemostatometry and assessment of thrombolysis was carried out in three groups of 72 renal transplant recipients. In one (triple, n = 21) immunosuppression was with cyclosporine, azathioprine, and prednisolone, while a second group (CsA, n = 29) received cyclosporine and prednisolone alone, and the third group (Aza, n = 22) azathioprine and prednisolone. Results were compared with those in 30 normal controls. A statistically significant increase in hemostasis compared with controls was seen in the triple group and in patients in the CsA group studied within 2 years of transplantation. Hemostasis in the Aza group did not differ from normal. All patients in this group had been transplanted more than 2 years before study. Thrombolysis times were significantly prolonged compared with controls in all three groups. Cyclosporine treatment is associated with enhanced hemostasis and reduced thrombolysis, especially during the first 2 years after renal transplantation. If these in vitro findings reflect events in vivo, this may throw light upon the pathogenesis of the obliterative arteriolopathy that is a feature of cyclosporine nephrotoxicity.This publication has 3 references indexed in Scilit:
- LIMITED VALUE OF IN-111 PLATELET SCINTIGRAPHY IN RENAL-TRANSPLANT PATIENTS RECEIVING CYCLOSPORINE1986
- Cyclosporine and Renal Prostaglandin E2 ProductionAnnals of Internal Medicine, 1985
- Effect of Cyclosporin A on prostacyclin synthesis by vascular tissueThrombosis Research, 1983